Mumbai, Aug. 10 -- Gland Pharma said that it has entered into a five-year manufacturing and supply agreement with a leading global pharmaceutical company for the technology transfer and development of 55 sterile injectable products.

The agreement covers the manufacturing and supply of oncology and non-oncology products across multiple injectable formats.

The portfolio includes products in vial, lyophilized vial, ampoule and pre-filled syringe formats, covering both conventional and complex injectables.

The agreement spans three manufacturing sites and is expected to generate annualised revenue of $90-100 million, with revenue contribution expected to commence from CY29.

The company also has scope to add more products and undertake tec...